NVO — Expected Completion of Esperoct® Clinical Trial

Expected Completion of Clinical Trial for ESK-001

Alumis Inc's clinical trial of ESK-001, aimed at evaluating the drug in participants with normal liver function and varying degrees of liver damage, is expected to complete by December 1, 2025. The trial, currently in Phase 1 and recruiting 48 participants, seeks to assess safety and efficacy. ESK-001 may present new treatment options for patients with liver conditions. The completion of this trial could impact Alumis's pipeline and future market strategy depending on the outcomes.

• www.clinicaltrials.gov/study/NCT06952634

Expected Completion of Clinical Trial Evaluating Efruxifermin

Akero Therapeutics, Inc. is expected to complete its clinical trial evaluating Efruxifermin (EFX) in subjects with Non-alcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Non-alcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) by October 1, 2026. The Phase 3 trial aims to assess the safety and tolerability of EFX compared to placebo and is currently enrolling up to 700 participants. Efruxifermin could provide a novel treatment option within this therapeutic area, which is significant as NASH and related liver diseases have a substantial unmet need in patient care.

• www.clinicaltrials.gov/study/NCT06161571

Expected Completion of Clinical Trial for ORX750

Centessa Pharmaceuticals plc is nearing the expected completion of its Phase 2 clinical trial for ORX750, a drug targeting narcolepsy and idiopathic hypersomnia, scheduled for December 1, 2025. ORX750 aims to mimic the action of orexin, a protein that aids wakefulness, potentially benefiting participants suffering from excessive daytime sleepiness associated with Narcolepsy Type 1, Narcolepsy Type 2, and Idiopathic Hypersomnia. The trial currently has 78 participants and is in the recruiting phase. The completion of this trial may have implications for future treatments in sleep disorders, aligning with Centessa's strategic focus on addressing unmet medical needs in this area.

Expected Completion of MaesTTRo Clinical Trial

AstraZeneca's MaesTTRo clinical trial for patients with transthyretin (ATTR) amyloidosis is expected to conclude on December 29, 2031. This international, non-interventional study aims to enroll approximately 1,600 patients, primarily focused on those with ATTR cardiomyopathy and hereditary polyneuropathy. The trial is currently in the recruiting phase, which started on June 25, 2024, and will include robust data collection from patient-reported outcomes and routine clinical information. This research is significant as it may enhance understanding of ATTR, potentially affecting treatment approaches and market dynamics for related therapies.